Page 6 - Loncode Institute News Today

Lund, February 9, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute...

FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular

Investegate announcements from Active Biotech, Active Biotech: Year End Report 2021

Data presented at ESMO in September provided clinical proof of concept for the intravenous administration of Transgene's patented oncolytic virus (Invir.IO platform)-significantly expanding the market

A conversation with Miao-Ping Chien, an experienced researcher and owner of a promising company to improve care for cancer patients.

LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In-Class immunotherapies

-- Adding deep preclinical and clinical immuno-oncology expertise to expand InteRNA's preclinical pipeline and accelerate clinical-stage lead candidate INT-1B3 -- InteRNA Technologies, a clinical-stage

PASADENA, CA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings,Inc. ( Nasdaq:LIXT ) announced entry into a collaboration with the Netherlands Cancer Institute, Amsterdam (NKI) , one of the

Press Release 30 September 2021 Immunicum Appoints New Experts in Cancer Immunology to Scientific Advisory Board Immunicum AB (publ; IMMU.ST)...

Press Release 30 September 2021 Immunicum Appoints New Experts in Cancer Immunology to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) today announced the appointment of Ada M.